AMAM(Delisted)
Ambrx BiopharmaยทNASDAQ
--
--(--)
AMAM fundamentals
Ambrx Biopharma (AMAM) released its earnings on Apr 26, 2022: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
Apr 26, 2022
EPS
Revenue
Revenue & Expenses
AMAM has released its 2023 Q3 earnings report, with revenue of 53.00K, reflecting a YoY change of -96.68%, and net profit of -22.99M, showing a YoY change of -47.67%. The Sankey diagram below clearly presents AMAM's revenue sources and cost distribution.
Key Indicators
Ambrx Biopharma (AMAM) key financial stats and ratios, covering profitability, financial health, and leverage.
Ambrx Biopharma (AMAM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Ambrx Biopharma (AMAM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Ambrx Biopharma (AMAM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Ambrx Biopharma (AMAM) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Ambrx Biopharma (AMAM) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
